Ovarian Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with epithelial ovarian cancer, fallopian tube cancer, or primary peritoneal cancer
- People who have a confirmed BRCA 1 or BRCA 2 gene mutation (either inherited or developed over time), verified by an approved laboratory
- People who are about to start a first-line maintenance treatment with a drug called Olaparib, either on its own or combined with another drug called bevacizumab
- People who are 18 years of age or older at the time of signing the consent form
- People who have a general health status rated as good or fully active (WHO performance score of 0 or 1) (confirm with trial site)
- People who are enrolled in the French Social Security system
- People who have signed an informed consent form before joining the study
Who may not be able to join:
- People who are currently being treated for another type of cancer
- People who have already started taking Olaparib
- People whose treatment plan calls for a PARP inhibitor drug other than Olaparib
- People who have a health condition that would make it unsafe to have the sample collection procedures required by the study (confirm with trial site)
- People whose personal, family, geographic, or social circumstances would make it impossible to follow the study schedule and procedures
- People who are in legal custody or under a legal protection order
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Phone: 05 31 15 51 01
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
The rate of patients (in the population of patients with disease progression) with disease progression that was preceded by the detection of BRCA1/2 reversion mutation in circulating tumour DNA (i.e. Sensitivity).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 27 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.